1. In Vivo
  2. >>Business Strategy

Genomiconomics.com

With the free-fall in dot com stocks, money has flowed--with a vengeance--into biotech. But the valuations are not sustainable: most of the new companies are shooting for a market far too small to support even half of the new competitors, and trying to sell only portions of what drug companies want to buy.

For two miserably chilly years, biotech executives sat back and watched the dot coms soar, jealously certain of the B2C and B2B business absurdity and eventual crash. They were, of course, right. drugstore.com Inc. , PlanetRx.com Inc. , Ventro Corp. , Neoforma.com Inc. are all trading 90+% below their high-water marks. The dotcomconomics which created them and made them briefly famous have equally undone them.

Now at least some of the money which once flowed towards new Internet sites is suddenly streaming into genomics companies,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics

 
• By David Wild

By offering free sequencing and embracing radical openness with global partners, Regeneron Genetics Center has gathered over 3 million samples, leading to the identification of over 30 drug targets now in Regeneron’s pipeline.

Podcast: EY’s Arda Ural On IPOs, Financial Markets And Tariffs

 
• By David Wild

EY's Arda Ural joins In Vivo to discuss the long-awaited recovery in biotech IPOs, the evolving capital markets landscape and how tariffs and TrumpRx are reshaping biopharma supply chains.

Celltrion USA’s New CMO Champions Regulatory Reform And Access

 
• By David Wild

Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.

CellProthera Targeting Heart Regeneration Where No Treatment Exists

 
• By David Wild

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

More from In Vivo

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 
• By Lucie Ellis-Taitt

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

Deals In Depth: October 2025

 
• By Maureen Riordan and Deanna Kamienski

Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.

Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines

 
• By Shannon Fisher and Heidi Chen

In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.